{'fraction_non_alphanumeric': 0.023809523809523808, 'fraction_numerical': 0.005291005291005291, 'mean_word_length': 5.485714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Liberty Asthma Venture Trial: Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma

We had the pleasure of discussing Dr. Klaus Rabe and colleagues’ Liberty Asthma Venture Trial at our Twitter based journal club (@respandsleepjc, #rsjc). We were honored to have one of the lead authors Dr. Nair join online for the discussion. VENTURE looked at the use of dupilumab in severe steroid dependent asthma. Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor, inhibiting both interleukin-4 and interleukin-13 signaling, and dampening type 2 inflammation. Treatment with dupilumab has been shown to reduce the rate of exacerbations and improve lung function in patients with uncontrolled moderate to severe asthma. Anti-interleukin-5 agents mepolizumab and benralizumab have both shown oral glucocorticoid sparing effects in patients with severe eosinophilic asthma, as reported in the SIRIUS and ZONDA trials, respectively. Dupilumab’s effectiveness in reducing oral glucocorticoid use and maintaining symptom control in these patients remains unclear. Discussion